StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 04 Jan 2023 06:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/Press+Releases/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html si-local-file:///var/storage/newsbody/2023/0104/21027828.html http://www.streetinsider.com/PRNewswire/Hadassah+Medical+Organization+and+Bar-Ilan+University+Collaborate+with+Immix+BioPharma+for+the+Further+Development+and+Commercialization+of+Next-Generation+CAR-T+Therapy/21027828.html Wed, 04 Jan 2023 06:00:00 -0400 A.22152539 A.41009862 HDST O.04153247 O.13812324 O.13812374 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/Press+Releases/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html si-local-file:///var/storage/newsbody/2022/1117/20865795.html http://www.streetinsider.com/PRNewswire/Myeloma+Investment+Fund+Invests+in+KAHR+to+Explore+Potential+of+KAHR%27s+Lead+Immunotherapy+Drug+Candidate+for+the+Treatment+of+Multiple+Myeloma/20865795.html Thu, 17 Nov 2022 04:00:00 -0400 A.34533727 HDST O.04153247 O.06963957 KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html si-local-file:///var/storage/newsbody/2021/0616/18565480.html http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html Wed, 16 Jun 2021 06:30:00 -0400 A.34533727 A.37393068 HDST KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html si-local-file:///var/storage/newsbody/2021/0616/18565480.html http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html Wed, 16 Jun 2021 06:30:00 -0400 A.34533727 A.37393068 HDST KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html si-local-file:///var/storage/newsbody/2021/0616/18565480.html http://www.streetinsider.com/Press+Releases/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html Wed, 16 Jun 2021 06:30:00 -0400 A.34533727 A.37393068 HDST KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline http://www.streetinsider.com/PRNewswire/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html si-local-file:///var/storage/newsbody/2021/0616/18565480.html http://www.streetinsider.com/PRNewswire/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html Wed, 16 Jun 2021 06:30:00 -0400 A.34533727 A.37393068 HDST KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline http://www.streetinsider.com/PRNewswire/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html si-local-file:///var/storage/newsbody/2021/0616/18565480.html http://www.streetinsider.com/PRNewswire/KAHR+Announces+%2446.5+Million+Financing+to+Advance+its+Multifunctional+Immunotherapeutic+Pipeline/18565480.html Wed, 16 Jun 2021 06:30:00 -0400 A.34533727 A.37393068 HDST